MAGEA3 and non-small cell lung carcinoma: In a study with MAGE-A3 immunotherapeutic in non-small cell lung cancer patients who received concurrent cisplatin/vinorelbine chemotherapy regimen, a robust MAGE-A3-specific antibody response was induced in all patients [40].